The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis.

ABSTRACT: The HER2-positive breast cancer subtype (HER2⁺-BC) displays a particularly aggressive behavior. Anti-HER2 therapies have significantly improved the survival of patients with HER2⁺-BC. However, a large number of patients become refractory to current targeted therapies, necessitating the development of new treatment strategies. Epigenetic regulators are commonly misregulated in cancer and represent attractive molecular therapeutic targets. Monoubiquitination of histone 2B (H2Bub1) by the heterodimeric ubiquitin ligase complex RNF20/RNF40 has been described to have tumor suppressor functions and loss of H2Bub1 has been associated with cancer progression. In this study, we utilized human tumor samples, cell culture models, and a mammary carcinoma mouse model with tissue-s

SUBMITTER: Wegwitz F 

PROVIDER: S-EPMC7568723 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature